Hypertension (Q55889453)

Europe PubMed Central

title

Hypertension (English)

0 references

Mark Caulfield

3

0 references

Dorairaj Prabhakaran

object named as

Dorairaj Prabhakaran

2

0 references

author name string

Neil R Poulter

1

0 references

Dorairaj Prabhakaran

2

0 references

Mark Caulfield

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

3

0 references

language of work or name

English

0 references

publication date

August 2015

0 references

22 August 2015

0 references

published in

The Lancet

0 references

volume

386

0 references

issue

9995

0 references

page(s)

801-812

0 references

801-12

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Hypertension in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Hypertension awareness, treatment and control in Africa: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Current and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat: an estimate from population studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Prevalence, risk factors and awareness of hypertension in India: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Blood pressure control in Italy: results of recent surveys on hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Hypertension management in England: a serial cross-sectional study from 1994 to 2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Cardiovascular disease, diabetes and established risk factors among populations of sub-Saharan African descent in Europe: a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Socio-economic status and blood pressure: an overview analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Advances in blood pressure genomics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The fetal origins of hypertension: a systematic review and meta-analysis of the evidence from animal experiments of maternal undernutrition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Systematic review and meta-analysis of preterm birth and later systolic blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Early life influences on cardio-metabolic disease risk in aboriginal populations--what is the evidence? A systematic review of longitudinal and case-control studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The associations of high birth weight with blood pressure and hypertension in later life: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Epigenomics of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Risk Stratification by Ambulatory Blood Pressure Monitoring Across JNC Classes of Conventional Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Making ambulatory blood pressure monitoring accessible in pharmacies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Risk stratification by self-measured home blood pressure across categories of conventional blood pressure: a participant-level meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

High prevalence of masked uncontrolled hypertension in people with treated hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Regression dilution of systolic and diastolic blood pressure in patients with established cerebrovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Medium-term variability of blood pressure and potential underdiagnosis of hypertension in patients with previous transient ischemic attack or minor stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Salt intake and cardiovascular disease: why are the data inconsistent?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Effect of lower sodium intake on health: systematic review and meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Urinary sodium and potassium excretion and risk of cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Fatal and Nonfatal Outcomes, Incidence of Hypertension, and Blood Pressure Changes in Relation to Urinary Sodium Excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Dietary salt intake and mortality in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Urinary sodium and potassium excretion, mortality, and cardiovascular events.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Lower levels of sodium intake and reduced cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The management of hypertension in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

An Effective Approach to High Blood Pressure Control: A Science Advisory From the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Longing for clinical excellence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Indapamide and bendrofluazide: a comparison in the management of essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Treatment of hypertension in patients 80 years of age or older

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Clinical results of the Verapamil in Hypertension and Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The effect of treatment on mortality in "mild" hypertension: results of the hypertension detection and follow-up program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Treatment of mild hypertension: a five year controlled drug trial. The Oslo study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Initial monotherapy and combination therapy and hypertension control the first year

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Impact of lower achieved blood pressure on outcomes in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Systolic and diastolic blood pressure control in antihypertensive drug trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Evidence Supporting a Systolic Blood Pressure Goal of Less Than 150 mm Hg in Patients Aged 60 Years or Older: The Minority View

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Effect of spironolactone on blood pressure in subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Navigating the shoals in hypertension: discovery and guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Updated ESH position paper on interventional therapy of resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

A controlled trial of renal denervation for resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Renal denervation for resistant hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Task shifting: the answer to the human resources crisis in Africa?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Substitution of doctors by nurses in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Hypertension, diabetes mellitus and task shifting in their management in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Can non-physician health-care workers assess and manage cardiovascular risk in primary care?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: Review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The role of Decision Support System (DSS) in prevention of cardiovascular disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Cellular phone and Internet-based individual intervention on blood pressure and obesity in obese patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment ran

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961468-9

7 January 2021